Compare PFSA & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFSA | ADXN |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | 2 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 11.1M |
| IPO Year | N/A | N/A |
| Metric | PFSA | ADXN |
|---|---|---|
| Price | $0.19 | $8.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.8M | 8.1K |
| Earning Date | 11-19-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.22 | N/A |
| 52 Week Low | $0.12 | $6.51 |
| 52 Week High | $12.76 | $12.05 |
| Indicator | PFSA | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.83 |
| Support Level | N/A | $7.59 |
| Resistance Level | N/A | $8.99 |
| Average True Range (ATR) | 0.00 | 0.52 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 50.97 |
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.